Abstract
Background Medication-overuse headache (MOH) is a chronic, secondary headache caused by excessive intake of symptomatic medications for an underlying headache, most often tension-type headache or migraine. Previously, elevated calcitonin-gene-related peptide (CGRP) levels were found in migraine patients increasing with migraine frequency and in animal MOH models. Aim To test whether MOH patients have increased CGRP levels before withdrawal therapy compared with healthy volunteers, and further, if the CGRP level would normalize after withdrawal in parallel with the headache-frequency decrease.
Highlights
Medication-overuse headache (MOH) is a chronic, secondary headache caused by excessive intake of symptomatic medications for an underlying headache, most often tension-type headache or migraine
Elevated calcitonin-gene-related peptide (CGRP) levels were found in migraine patients increasing with migraine frequency and in animal MOH models
Aim To test whether MOH patients have increased CGRP levels before withdrawal therapy compared with healthy volunteers, and further, if the CGRP level would normalize after withdrawal in parallel with the headache-frequency decrease
Summary
Medication-overuse headache (MOH) is a chronic, secondary headache caused by excessive intake of symptomatic medications for an underlying headache, most often tension-type headache or migraine. Elevated calcitonin-gene-related peptide (CGRP) levels were found in migraine patients increasing with migraine frequency and in animal MOH models. Aim To test whether MOH patients have increased CGRP levels before withdrawal therapy compared with healthy volunteers, and further, if the CGRP level would normalize after withdrawal in parallel with the headache-frequency decrease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
